Want to see JP:206A full AI Analyst Report?
206A Stock Chart & Stats
¥160.00
-¥4.00(-1.25%)
At close: 4:00 PM EST
¥160.00
-¥4.00(-1.25%)
Day’s Range― - ―
52-Week Range¥125.00 - ¥279.00
Previous CloseN/A
Volume305.30K
Average Volume (3M)2.26M
Market Cap
¥5.73B
Enterprise Value¥3.22B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.60
Shares Outstanding36,964,000
10 Day Avg. Volume1,556,930
30 Day Avg. Volume2,256,993
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.27
Price to Sales (P/S)9.06
P/FCF Ratio-4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery PlatformPRISM BioLab's proprietary discovery technologies targeting protein–protein interactions represent a durable scientific moat. A replicable platform can generate multiple drug candidates, sustain R&D productivity, and create long-term value beyond any single asset, supporting pipeline resilience.
Debt-free Balance SheetHaving no reported debt materially lowers financial risk and provides flexibility to fund R&D or pursue partnerships. This structural strength reduces near-term solvency pressure, enabling strategic choices (licensing, staged financing) without mandatory interest or principal servicing constraints.
Sizable Recent Revenue GrowthSustained top-line growth (noted ~74% recent increase) indicates improving commercial traction or successful advancement of programs. Durable revenue expansion can underpin future operating leverage if management controls costs and converts scale into sustainable margins over the medium term.
Bears Say
Persistent Unprofitable OperationsChronic negative EBIT and net income across multiple years show the business is not yet generating operating profits. Persistent unprofitability increases reliance on external funding, constrains reinvestment capacity, and raises execution risk unless cost structure or revenue quality improves.
Deteriorating Cash GenerationOperating cash flow has swung negative and worsened, while free cash flow is negative most years. Accelerating cash burn is a structural funding risk for a biotech with R&D intensity, increasing probability of dilutive financings or constrained program timelines absent new capital or partnerships.
Negative Returns And Volatile EquityStrongly negative ROE and fluctuating equity reflect shareholder value erosion and financing dynamics. Over several years this signals that capital deployed has not produced returns, raising long-term investor risk and implying management must materially improve capital efficiency.
PRISM BioLab Co. LTD News
206A FAQ
What was PRISM BioLab Co. LTD’s price range in the past 12 months?
PRISM BioLab Co. LTD lowest stock price was ¥125.00 and its highest was ¥279.00 in the past 12 months.
What is PRISM BioLab Co. LTD’s market cap?
PRISM BioLab Co. LTD’s market cap is ¥5.73B.
When is PRISM BioLab Co. LTD’s upcoming earnings report date?
PRISM BioLab Co. LTD’s upcoming earnings report date is Aug 14, 2026 which is in 11 days.
How were PRISM BioLab Co. LTD’s earnings last quarter?
PRISM BioLab Co. LTD released its earnings results on May 14, 2026. The company reported -¥8.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥8.6.
Is PRISM BioLab Co. LTD overvalued?
According to Wall Street analysts PRISM BioLab Co. LTD’s price is currently Overvalued.
Does PRISM BioLab Co. LTD pay dividends?
PRISM BioLab Co. LTD does not currently pay dividends.
What is PRISM BioLab Co. LTD’s EPS estimate?
PRISM BioLab Co. LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PRISM BioLab Co. LTD have?
PRISM BioLab Co. LTD has 36,964,000 shares outstanding.
What happened to PRISM BioLab Co. LTD’s price movement after its last earnings report?
PRISM BioLab Co. LTD reported an EPS of -¥8.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of PRISM BioLab Co. LTD?
Currently, no hedge funds are holding shares in JP:206A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PRISM BioLab Co. LTD
PRISM Pharma Co., Ltd. is a pharmaceutical enterprise dedicated to identifying and advancing small molecule compounds. Its core mission involves modulating protein-protein interactions. The company leverages a proprietary protein secondary structure mimetic library to regulate interactions between proteins within cells. A key product in its development pipeline is PRI-724, an anti-cancer CP/Catenin inhibitor. This drug targets both mature cancer cells and cancer stem cells, inducing them to transition from uncontrolled proliferation to differentiation. Hiroyuki Kouji founded the organization on November 2, 2006, and it is headquartered in Fujisawa, Japan.
Technical Analysis
StemRIM Inc.
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―